Marc d'Abbadie

McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY.

Absynth Biologics Ltd. develops and manufactures immunological prophylaxis, novel vaccines and therapies. The company was founded by Simon J. Foster in 2007 and is headquartered in Alderley Edge, the United Kingdom.

Zilico Ltd. develops medical device to detect cervical cancer and pre-cancerous cells in the cervix. It focuses on developing a research-based instrument into a device (system) appropriate for commercial manufacture and routine use by medical practitioners. The firm consists of a handheld device and a base unit together with a single-use disposable sleeve for each test. The company was founded by John Tidy and Brian Brown on February 28, 2006 and is headquartered in Manchester, the United Kingdom.

Evgen Ltd. develops novel glucosinolate based products for the prevention and treatment of human disease. It engages in the clinical stage drug development that lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. Its activities also include carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer. The firm holds proprietary technology that enables sulforaphane to be synthesized and then subsequently stabilized for pharmaceutical application. The company was founded by Dr. Stephen Franklin on October 18, 2007 and is headquartered in Liverpool, the United Kingdom.

SPARK Impact Ltd (SPARK Impact) is a venture capital firm founded in 2010. The firm is headquartered in North East, United Kingdom.

Videregen Ltd. operates a regenerative medicine company created to address the chronic shortage of organs for transplantation in the field of tissue decellularisation, regenerative technologies and translation from laboratory to market. Its platform technology uses decellularised organ scaffolds seeded with the patient’s own cells to create non-immunogenic, regenerative bespoke organ replacements. The company was founded by Stephen Bloor in 2011 and is headquartered in Liverpool, The United Kingdom.